Tags

Type your tag names separated by a space and hit enter

Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations.
Clin Infect Dis. 2015 May 01; 60(9):1398-404.CI

Abstract

Miltefosine is the only recognized oral agent with potential to treat leishmaniasis. Miltefosine had demonstrated very good cure rates for visceral leishmaniasis (VL) in India, Nepal, and Bangladesh, but high rates of clinical failures have been recently reported. Moderate efficacy has been observed for VL in East Africa, whereas data from Mediterranean countries and Latin America are scarce. Results have not been very promising for patients coinfected with VL and human immunodeficiency virus. However, miltefosine's long half-life and its oral administration could make it a good option for maintenance prophylaxis. Good evidence of efficacy has been documented in Old World cutaneous leishmaniasis (CL), and different cure rates among New World CL have been obtained depending on the geographical areas and species involved. Appropriate regimens for New World mucocutaneous leishmaniasis need to be established, although longer treatment duration seems to confer better results. Strategies to prevent the development and spread of miltefosine resistance are urgently needed.

Authors+Show Affiliations

Tropical Medicine Centre, Infectious Diseases Department, Ramón y Cajal Hospital, Madrid, Spain.Tropical Medicine Centre, Infectious Diseases Department, Ramón y Cajal Hospital, Madrid, Spain.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25601455

Citation

Monge-Maillo, Begoña, and Rogelio López-Vélez. "Miltefosine for Visceral and Cutaneous Leishmaniasis: Drug Characteristics and Evidence-based Treatment Recommendations." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 60, no. 9, 2015, pp. 1398-404.
Monge-Maillo B, López-Vélez R. Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations. Clin Infect Dis. 2015;60(9):1398-404.
Monge-Maillo, B., & López-Vélez, R. (2015). Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 60(9), 1398-404. https://doi.org/10.1093/cid/civ004
Monge-Maillo B, López-Vélez R. Miltefosine for Visceral and Cutaneous Leishmaniasis: Drug Characteristics and Evidence-based Treatment Recommendations. Clin Infect Dis. 2015 May 1;60(9):1398-404. PubMed PMID: 25601455.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations. AU - Monge-Maillo,Begoña, AU - López-Vélez,Rogelio, Y1 - 2015/01/18/ PY - 2014/06/24/received PY - 2014/12/23/accepted PY - 2015/1/21/entrez PY - 2015/1/21/pubmed PY - 2016/1/26/medline KW - cutaneous leishmaniasis KW - leishmaniasis KW - miltefosine KW - therapy KW - visceral leishmaniasis SP - 1398 EP - 404 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 60 IS - 9 N2 - Miltefosine is the only recognized oral agent with potential to treat leishmaniasis. Miltefosine had demonstrated very good cure rates for visceral leishmaniasis (VL) in India, Nepal, and Bangladesh, but high rates of clinical failures have been recently reported. Moderate efficacy has been observed for VL in East Africa, whereas data from Mediterranean countries and Latin America are scarce. Results have not been very promising for patients coinfected with VL and human immunodeficiency virus. However, miltefosine's long half-life and its oral administration could make it a good option for maintenance prophylaxis. Good evidence of efficacy has been documented in Old World cutaneous leishmaniasis (CL), and different cure rates among New World CL have been obtained depending on the geographical areas and species involved. Appropriate regimens for New World mucocutaneous leishmaniasis need to be established, although longer treatment duration seems to confer better results. Strategies to prevent the development and spread of miltefosine resistance are urgently needed. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/25601455/Miltefosine_for_visceral_and_cutaneous_leishmaniasis:_drug_characteristics_and_evidence_based_treatment_recommendations_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/civ004 DB - PRIME DP - Unbound Medicine ER -